Effect of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance in Adolescents With Cystic Fibrosis
Authors' conclusion
ETI may improve glucose tolerance in adolescents with CF by preserving insulin secretion. One-hour glucose during the OGTT helps to detect risk for AGT after ETI treatment.
Study context
- Population
- Adolescents with cystic fibrosis starting elexacaftor/tezacaftor/ivacaftor (ETI) (age 14.1 ± 1.5 years)
- Participants
- 106 adolescents
- Exposure
- Baseline normal glucose tolerance (NGT) vs abnormal glucose tolerance (AGT) before and after ETI
- NGTn = 75reference
- AGTn = 31
- Outcome
- Effect of ETI on glucose tolerance (OGTT)
- Follow-up
- 12 months
Main finding
As reported in the abstract
Glucose tolerance after ETI
- AGT: reduction of 2-hour glucose
- P = .006
- AGT reversed to NGT
- 15 of 31 (48%)
- NGT progressed to AGT
- 9 of 75 (17%)
- Cystic fibrosis (CF)-related diabetes at baseline reversed to AGT
- 3 participants
Observational data: associations, not effects.
Further findings
BMI z score and FEV1
- ETI increased BMI z score and FEV1
- P < 0.001
Baseline 1-hour glucose ≥8.7 mmol/L (157 mg/dL) to identify AGT at 12 months
- Sensitivity
- 80%
- OR
- 1.51 [1.20-1.92]; P = .001
24-month oral glucose tolerance test (OGTT)
- Participants with 24-month OGTT confirming preserved insulin secretion
- 20
Original publication
Effect of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance in Adolescents With Cystic Fibrosis. J Clin Endocrinol Metab. Published 20 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →